Kyntra Bio, Inc. KYNB
Set alert
As of Nov 2, 10:23 AM ET
- YTD
- -47.95%
- 1 year
- -58.90%
- Open
- 4.63
- Prev close
- 4.57
- Mkt cap
- 18.50M
- Vol
- 1.44K
- Avg vol
- 21.68K
- EPS
- -7.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.57
- High
- 4.63
News
-
2 weeks ago benzinga.com
Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35
Maxim Group analyst Michael Okunewitch initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $35.
-
3 weeks ago defenseworld.net
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
1 month ago globenewswire.com
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of…
-
1 month ago benzinga.com
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.
2 months ago globenewswire.com
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.
-
2 months ago benzinga.com
Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
Company reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 million Company accelerated payment of $42.6 million upfront, bringing total payments…
2 months ago globenewswire.com
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project…
2 months ago seekingalpha.com
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.
-
2 months ago benzinga.com
UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.18) by 47.17 percent. This is a 148.94 percent decrease over losses of…
2 months ago benzinga.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript
On Thursday, Kyntra Bio (NASDAQ:KYNB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings…
2 months ago globenewswire.com
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.
3 months ago zacks.com
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 months ago defenseworld.net
Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)
Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two…
3 months ago benzinga.com
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, SPCX, KC, WELL, KYNB have coverage initiated.
-
3 months ago benzinga.com
Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35
Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform rating and announces Price Target of $35.
-
4 months ago benzinga.com
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients
The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met the criteria of HTB (≥ 4 units pRBCs per 8-week period for 2 consecutive 8-week periods) per…
4 months ago globenewswire.com
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in…
-
4 months ago benzinga.com
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.
5 months ago seekingalpha.com
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estimate of a loss of $3.36. This compares to a loss of $4 per share a year ago.
-
5 months ago benzinga.com
Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent decrease over earnings of $1.15 per share from the same period last year. The company reported $3.738…
5 months ago globenewswire.com
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company's recent developments.
6 months ago globenewswire.com
Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a…
6 months ago zacks.com
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
6 months ago globenewswire.com
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April…
7 months ago seekingalpha.com
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
-
7 months ago benzinga.com
Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst consensus estimate of $(3.71) by 2.56 percent. This is a 80.5 percent decrease over losses of $(2.00)…
7 months ago globenewswire.com
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and…
-
7 months ago benzinga.com
Earnings Scheduled For March 16, 2026
Earnings Scheduled For March 16, 2026
7 months ago zacks.com
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 months ago globenewswire.com
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16…
8 months ago benzinga.com
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.